These findings further reveal a distinct molecular architecture in metastatic CRC, characterized by enhanced EGFR signaling, metabolic reprogramming and stress adaptation mechanisms, potentially contributing to Panitumumab resistance. The gene discussed is EGFR; the disease is colorectal carcinoma.